Novel detection strategies for drug discovery

The Human Genome Project is expected to increase the number of potential drug targets from the current figure of 500 to ∼3000–4000. This increased number of targets, and increasing knowledge of signaling-pathway networks and their complexities, sets new demands for efficiency on HTS assay technologi...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2002-09, Vol.7 (18), p.S150-S156
Main Authors: Hemmilä, Ilkka A., Hurskainen, Pertti
Format: Article
Language:English
Subjects:
Animals
cAMP
DELFIA
FRET
Functional assays
GTP
Human Genome Project
Humans
Internalization
IP3
Ligands
Pharmacology - trends
Receptor trafficking
Receptors, Drug - drug effects
Receptors, Drug - genetics
Signal Transduction - genetics
β-Arrestin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3
cites cdi_FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3
container_end_page S156
container_issue 18
container_start_page S150
container_title Drug discovery today
container_volume 7
creator Hemmilä, Ilkka A.
Hurskainen, Pertti
description The Human Genome Project is expected to increase the number of potential drug targets from the current figure of 500 to ∼3000–4000. This increased number of targets, and increasing knowledge of signaling-pathway networks and their complexities, sets new demands for efficiency on HTS assay technologies. Assessment of the total efficacy of a given drug candidate requires not only the classical assays, but also a wide variety of assays related to signaling cascades and cellular functions. Discrete functional assays traditionally involved Ca2+ flux, kinases and cAMP, but today extend to the whole signaling network, from ligand binding to expression. This review discusses emerging novel non-radioisotopic assays, such as ligand-stimulated GTP-binding, the inositol triphosphate assay, cellular receptor trafficking, and protein–protein interactions.
doi_str_mv 10.1016/S1359-6446(02)02390-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72833013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644602023905</els_id><sourcerecordid>18585090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCaCsECwCYzt27RVCFS-pggWwthJ7XAWlTbGTSv173AdiyWpmce7c0SHknMINBSpv3ykXOpdFIa-AXQPjGnJxQIZUjVUuFGeHaf9FBuQkxi8AyrSQx2RAmSikUmxI8td2hU3msEPb1e0ii10oO5zVGDPfhsyFfpa5OtqEhfUpOfJlE_FsP0fk8_HhY_KcT9-eXib309xyzbrceq-1lSVXwFSFkjvgshhTjqUVCrzmlGFRCeAgqAWNTlWFY17oFKPU8xG53N1dhva7x9iZeXoBm6ZcYNtHM2aKc6D8X5AqoQRoSKDYgTa0MQb0ZhnqeRnWhoLZCDVboWZjywAzW6FGpNzFvqCv5uj-UnuDCbjbAZh8rGoMJtoaFxZdHZJS49r6n4ofIF-Dwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18585090</pqid></control><display><type>article</type><title>Novel detection strategies for drug discovery</title><source>ScienceDirect Freedom Collection</source><creator>Hemmilä, Ilkka A. ; Hurskainen, Pertti</creator><creatorcontrib>Hemmilä, Ilkka A. ; Hurskainen, Pertti</creatorcontrib><description>The Human Genome Project is expected to increase the number of potential drug targets from the current figure of 500 to ∼3000–4000. This increased number of targets, and increasing knowledge of signaling-pathway networks and their complexities, sets new demands for efficiency on HTS assay technologies. Assessment of the total efficacy of a given drug candidate requires not only the classical assays, but also a wide variety of assays related to signaling cascades and cellular functions. Discrete functional assays traditionally involved Ca2+ flux, kinases and cAMP, but today extend to the whole signaling network, from ligand binding to expression. This review discusses emerging novel non-radioisotopic assays, such as ligand-stimulated GTP-binding, the inositol triphosphate assay, cellular receptor trafficking, and protein–protein interactions.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/S1359-6446(02)02390-5</identifier><identifier>PMID: 12546882</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; cAMP ; DELFIA ; FRET ; Functional assays ; GTP ; Human Genome Project ; Humans ; Internalization ; IP3 ; Ligands ; Pharmacology - trends ; Receptor trafficking ; Receptors, Drug - drug effects ; Receptors, Drug - genetics ; Signal Transduction - genetics ; β-Arrestin</subject><ispartof>Drug discovery today, 2002-09, Vol.7 (18), p.S150-S156</ispartof><rights>2002 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3</citedby><cites>FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12546882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hemmilä, Ilkka A.</creatorcontrib><creatorcontrib>Hurskainen, Pertti</creatorcontrib><title>Novel detection strategies for drug discovery</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>The Human Genome Project is expected to increase the number of potential drug targets from the current figure of 500 to ∼3000–4000. This increased number of targets, and increasing knowledge of signaling-pathway networks and their complexities, sets new demands for efficiency on HTS assay technologies. Assessment of the total efficacy of a given drug candidate requires not only the classical assays, but also a wide variety of assays related to signaling cascades and cellular functions. Discrete functional assays traditionally involved Ca2+ flux, kinases and cAMP, but today extend to the whole signaling network, from ligand binding to expression. This review discusses emerging novel non-radioisotopic assays, such as ligand-stimulated GTP-binding, the inositol triphosphate assay, cellular receptor trafficking, and protein–protein interactions.</description><subject>Animals</subject><subject>cAMP</subject><subject>DELFIA</subject><subject>FRET</subject><subject>Functional assays</subject><subject>GTP</subject><subject>Human Genome Project</subject><subject>Humans</subject><subject>Internalization</subject><subject>IP3</subject><subject>Ligands</subject><subject>Pharmacology - trends</subject><subject>Receptor trafficking</subject><subject>Receptors, Drug - drug effects</subject><subject>Receptors, Drug - genetics</subject><subject>Signal Transduction - genetics</subject><subject>β-Arrestin</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EoqXwCaCsECwCYzt27RVCFS-pggWwthJ7XAWlTbGTSv173AdiyWpmce7c0SHknMINBSpv3ykXOpdFIa-AXQPjGnJxQIZUjVUuFGeHaf9FBuQkxi8AyrSQx2RAmSikUmxI8td2hU3msEPb1e0ii10oO5zVGDPfhsyFfpa5OtqEhfUpOfJlE_FsP0fk8_HhY_KcT9-eXib309xyzbrceq-1lSVXwFSFkjvgshhTjqUVCrzmlGFRCeAgqAWNTlWFY17oFKPU8xG53N1dhva7x9iZeXoBm6ZcYNtHM2aKc6D8X5AqoQRoSKDYgTa0MQb0ZhnqeRnWhoLZCDVboWZjywAzW6FGpNzFvqCv5uj-UnuDCbjbAZh8rGoMJtoaFxZdHZJS49r6n4ofIF-Dwg</recordid><startdate>20020915</startdate><enddate>20020915</enddate><creator>Hemmilä, Ilkka A.</creator><creator>Hurskainen, Pertti</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20020915</creationdate><title>Novel detection strategies for drug discovery</title><author>Hemmilä, Ilkka A. ; Hurskainen, Pertti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>cAMP</topic><topic>DELFIA</topic><topic>FRET</topic><topic>Functional assays</topic><topic>GTP</topic><topic>Human Genome Project</topic><topic>Humans</topic><topic>Internalization</topic><topic>IP3</topic><topic>Ligands</topic><topic>Pharmacology - trends</topic><topic>Receptor trafficking</topic><topic>Receptors, Drug - drug effects</topic><topic>Receptors, Drug - genetics</topic><topic>Signal Transduction - genetics</topic><topic>β-Arrestin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hemmilä, Ilkka A.</creatorcontrib><creatorcontrib>Hurskainen, Pertti</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hemmilä, Ilkka A.</au><au>Hurskainen, Pertti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel detection strategies for drug discovery</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2002-09-15</date><risdate>2002</risdate><volume>7</volume><issue>18</issue><spage>S150</spage><epage>S156</epage><pages>S150-S156</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-Review-3</notes><notes>content type line 23</notes><notes>ObjectType-Feature-3</notes><notes>ObjectType-Review-1</notes><abstract>The Human Genome Project is expected to increase the number of potential drug targets from the current figure of 500 to ∼3000–4000. This increased number of targets, and increasing knowledge of signaling-pathway networks and their complexities, sets new demands for efficiency on HTS assay technologies. Assessment of the total efficacy of a given drug candidate requires not only the classical assays, but also a wide variety of assays related to signaling cascades and cellular functions. Discrete functional assays traditionally involved Ca2+ flux, kinases and cAMP, but today extend to the whole signaling network, from ligand binding to expression. This review discusses emerging novel non-radioisotopic assays, such as ligand-stimulated GTP-binding, the inositol triphosphate assay, cellular receptor trafficking, and protein–protein interactions.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12546882</pmid><doi>10.1016/S1359-6446(02)02390-5</doi></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2002-09, Vol.7 (18), p.S150-S156
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_72833013
source ScienceDirect Freedom Collection
subjects Animals
cAMP
DELFIA
FRET
Functional assays
GTP
Human Genome Project
Humans
Internalization
IP3
Ligands
Pharmacology - trends
Receptor trafficking
Receptors, Drug - drug effects
Receptors, Drug - genetics
Signal Transduction - genetics
β-Arrestin
title Novel detection strategies for drug discovery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T03%3A13%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20detection%20strategies%20for%20drug%20discovery&rft.jtitle=Drug%20discovery%20today&rft.au=Hemmil%C3%A4,%20Ilkka%20A.&rft.date=2002-09-15&rft.volume=7&rft.issue=18&rft.spage=S150&rft.epage=S156&rft.pages=S150-S156&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/S1359-6446(02)02390-5&rft_dat=%3Cproquest_cross%3E18585090%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c392t-cff99c6a38028be63d0364713eac580f9312e4b503051c09ed8b4d2f5999c11f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18585090&rft_id=info:pmid/12546882&rfr_iscdi=true